Abstract:Objective: The estimand framework offers a structured approach to define the treatment effect to be estimated in a clinical study. Defining the estimand upfront helps formulating the research question and informs study design, data collection and statistical analysis methods. Since the Trials within Cohorts (TwiCs) design has unique characteristics, the objective of this study is to describe considerations and provide guidance for formulating estimands for TwiCs studies. Methods: The key attributes of an estimand are the target population, treatments that are compared, the endpoint, intercurrent events and their handling, and the population-level summary measure. The estimand framework was applied retrospectively to two TwiCs studies: the SPONGE and UMBRELLA Fit trial. The aim is to demonstrate how the estimand framework can be implemented in TwiCs studies, thereby focusing on considerations relevant for defining the estimand. Three estimands were defined for both studies. For the SPONGE trial, estimators were derived. Results: Intercurrent events considered to occur exclusively or more frequently in TwiCs studies compared to conventional randomized trials included intervention refusal after randomization, misalignment of timing of routine cohort measurements and the intervention period, and participants in the control arm initiating treatments similar to the studied intervention. Considerations for handling refusal after randomization related to decisions on whether the target population should include all eligible participants or the subpopulation that would accept (or undergo) the intervention when offered. Considerations for handling treatment initiation in the control arm and misalignments of timing related to decisions on whether such events should be considered part of treatment policy or whether interest is in a hypothetical scenario where such events do not occur. Conclusion: The TwiCs study design has unique features that pose specific considerations when formulating an estimand. The examples in this study can provide guidance in the definition of estimands in future TwiCs studies.

Current developments of the estimand concept

Application of the estimand framework for an emulated trial using reference based multiple imputation to investigate informative censoring

Estimands in Hematologic Oncology Trials

Tailored guidance to apply the Estimand framework to Trials within Cohorts (TwiCs) studies

Estimands in Real-World Evidence Studies

Defining estimands in clinical trials: A unified procedure

Defining estimands using a mix of strategies to handle intercurrent events in clinical trials

Connecting Instrumental Variable methods for causal inference to the Estimand Framework

Translating questions to estimands in randomized clinical trials with intercurrent events

Application of estimand framework to the design and analysis of multi-regional clinical trials

Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice

Applying the estimands framework to non-inferiority trials: guidance on choice of hypothetical estimands for non-adherence and comparison of estimation methods

What matters most? Different stakeholder perspectives on estimands for an invented case study in COPD

Decentralized Clinical Trials: Scientific Considerations Through the Lens of the Estimand Framework

Estimands in clinical trials of complex disease processes

Time-to-event estimands and loss to follow-up in oncology in light of the estimands framework

On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies

Time‐to‐event estimands and loss to follow‐up in oncology in light of the estimands guidance

Implementation of ICH E9 (R1): a few points learned during the COVID-19 pandemic

Treatment Effect Quantification for Time-to-event Endpoints -- Estimands, Analysis Strategies, and beyond

Estimation methods for estimands using the treatment policy strategy; a simulation study based on the PIONEER 1 Trial